Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.404 FI de cinco anos: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volume 40, 2020 Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v18.i5.10
pages 389-418

CD28/B7 Costimulation: A Review

Edward A. Greenfield
Department Of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115. Center For Neurological Diseases, Brigham and Women's Hospital, Boston, MA 02115
Khuong A. Nguyen
Department Of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115
Vijay K. Kuchroo
Center For Neurological Diseases, Brigham and Women's Hospital, Boston, MA 02115


The current model of T cell activation requires two signals. The first signal is specific, requiring T cell receptor recognition and binding to MHC/Antigen presented by an antigen-presenting cell. The second signal is nonspecific, resulting from the binding of B7 ligand on the antigen-presenting cell with its receptor, CD28, on the T cell. If both signals are provided, the T cell will proliferate and secrete cytokines. Recently, it has been shown that CTLA4, another receptor for B7 that is upregulated following T cell after activation, can deliver an inhibitory signal, downregulating T cell proliferation. The B7 family of ligands has two family members, B7-1 and B7-2. They both bind to CD28 and CTLA4, but they differ in their binding affinity, structure, and temporal expression. Considerable research has been done on the CD28/B7 costimulatory pathway. Different ways of manipulating this pathway could provide insights into the mechanism and treatment of opposing pathological states. Blocking the CD28/B7 pathway could result in immunosuppression, with implications for the treatment of autoimmune diseases, organ transplantation, and graft vs. host disease. Activating the CD28/B7 pathway could be useful for including the immune system to recognize and eliminate tumors that evade the immune system. Finally, the CD28/B7 pathway could be involved with maintaining immune tolerance, as recent studies suggest the preferential binding of the B7-CTLA4 pathway results in the down-regulation of the responding T cells. Thus, the B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses.

Palavras-chave: costimulation, CD28, B7, CTLA4.

Articles with similar content:

The Inflammasome and Its Regulation
Critical Reviews™ in Immunology, Vol.34, 2014, issue 1
Hideki Hara, Kohsuke Tsuchiya
Regulation of Mast Cell Responses in Health and Disease
Critical Reviews™ in Immunology, Vol.31, 2011, issue 6
Michael A. Beaven, Alasdair M. Gilfillan
Is the CD200/CD200 Receptor Interaction More Than Just a Myeloid Cell Inhibitory Signal?
Critical Reviews™ in Immunology, Vol.26, 2006, issue 3
Janet Liversidge, Konstantinos Minas
Targeting OX40 and OX40L for the Treatment of Autoimmunity and Cancer
Critical Reviews™ in Immunology, Vol.27, 2007, issue 5
Andrew D. Weinberg, William L. Redmond
Steel Factor and c-kit Protooncogene: Genetic Lessons in Signal Transduction
Critical Reviews™ in Oncogenesis, Vol.5, 1994, issue 2-3
Janna M. Blechman, David Givol, Yosef Yarden, Sima Lev